Leerink Partnrs Analysts Lift Earnings Estimates for BSX

Key Points

• Leerink Partners has raised its earnings forecast for Boston Scientific, projecting Q2 2026 earnings per share at $0.86, an increase from the prior estimate of $0.84.
• The consensus estimate for Boston Scientific's current full-year earnings stands at $2.85 per share, with projected earnings for FY2026 at $3.43 EPS.
• Institutional investors hold 89.07% of Boston Scientific's shares, indicating strong support from large investment firms.

Boston Scientific Corporation (NYSE:BSX - Free Report) - Equities research analysts at Leerink Partnrs upped their Q2 2026 EPS estimates for shares of Boston Scientific in a research report issued on Tuesday, September 9th. Leerink Partnrs analyst M. Kratky now anticipates that the medical equipment provider will post earnings of $0.86 per share for the quarter, up from their prior estimate of $0.84. Leerink Partnrs has a "Strong-Buy" rating on the stock. The consensus estimate for Boston Scientific's current full-year earnings is $2.85 per share. Leerink Partnrs also issued estimates for Boston Scientific's Q4 2026 earnings at $0.94 EPS and FY2026 earnings at $3.43 EPS.

A number of other brokerages also recently issued reports on BSX. Needham & Company LLC reiterated a "buy" rating and issued a $121.00 price target on shares of Boston Scientific in a report on Thursday. Oppenheimer upgraded shares of Boston Scientific from a "market perform" rating to an "outperform" rating and upped their price target for the company from $118.00 to $125.00 in a report on Monday, September 8th. Raymond James Financial upped their price target on shares of Boston Scientific from $121.00 to $124.00 and gave the company a "strong-buy" rating in a report on Thursday, July 24th. Leerink Partners began coverage on shares of Boston Scientific in a report on Monday, June 16th. They set an "outperform" rating and a $118.00 price target on the stock. Finally, Robert W. Baird upped their price target on shares of Boston Scientific from $117.00 to $123.00 and gave the company an "outperform" rating in a report on Thursday, July 24th. Three research analysts have rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat.com, Boston Scientific presently has a consensus rating of "Buy" and an average target price of $118.04.

Boston Scientific Price Performance

NYSE BSX traded down $1.63 on Wednesday, reaching $102.71. The company had a trading volume of 10,541,837 shares, compared to its average volume of 6,118,901. The company has a quick ratio of 0.82, a current ratio of 1.37 and a debt-to-equity ratio of 0.49. The stock has a market capitalization of $152.19 billion, a PE ratio of 61.14, a price-to-earnings-growth ratio of 2.51 and a beta of 0.65. The firm's 50 day moving average price is $104.86 and its 200 day moving average price is $102.26. Boston Scientific has a 12 month low of $80.64 and a 12 month high of $109.50.

Boston Scientific (NYSE:BSX - Get Free Report) last announced its quarterly earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.72 by $0.03. The company had revenue of $5.06 billion for the quarter, compared to the consensus estimate of $4.89 billion. Boston Scientific had a net margin of 13.55% and a return on equity of 19.21%. Boston Scientific's revenue for the quarter was up 22.8% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.62 EPS. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS.

Insider Activity at Boston Scientific

In other Boston Scientific news, Director Edward J. Ludwig sold 4,000 shares of the business's stock in a transaction dated Friday, July 25th. The shares were sold at an average price of $106.03, for a total value of $424,120.00. Following the completion of the sale, the director directly owned 18,479 shares of the company's stock, valued at $1,959,328.37. The trade was a 17.79% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Arthur C. Butcher sold 17,313 shares of the business's stock in a transaction dated Friday, August 1st. The shares were sold at an average price of $104.63, for a total transaction of $1,811,459.19. Following the completion of the sale, the executive vice president directly owned 23,600 shares of the company's stock, valued at approximately $2,469,268. This trade represents a 42.32% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 174,214 shares of company stock valued at $18,397,457 in the last quarter. Corporate insiders own 0.50% of the company's stock.

Institutional Investors Weigh In On Boston Scientific

Several large investors have recently added to or reduced their stakes in BSX. Investment Management Corp VA ADV purchased a new stake in shares of Boston Scientific in the 4th quarter worth approximately $25,000. Sunbeam Capital Management LLC purchased a new stake in shares of Boston Scientific in the 4th quarter worth approximately $26,000. 1248 Management LLC purchased a new stake in shares of Boston Scientific in the 1st quarter worth approximately $26,000. FWL Investment Management LLC purchased a new stake in shares of Boston Scientific in the 2nd quarter worth approximately $26,000. Finally, Y.D. More Investments Ltd purchased a new stake in shares of Boston Scientific in the 1st quarter worth approximately $27,000. 89.07% of the stock is owned by hedge funds and other institutional investors.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.